Lee Swanson Research Update

EpiCor® Appears to Reduce Allergy Symptoms

December 2009

"Allergic rhinitis (AR) impacts around 25% of the worldwide population," according to researchers writing in the journal Advances in Therapy. "However, cost, safety and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion."

The researchers continued: "Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound (EpiCor); therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms."

The randomized, double-blind, placebo-controlled study gave 96 healthy test subjects with recent history of seasonal allergies and AR 500 mg per day of EpiCor or a placebo during a 12-week period of the highest recorded concentrations of total pollen counts for the Midwest geographic area.

Results were measured with in-clinic examinations, validated questionnaires and diaries and serologic analysis at baseline, six and 12 weeks. The study found EpiCor significantly reduced the severity of specific AR symptoms, including nasal congestion and rhinorrhea (runny nose).

Researchers concluded: "This yeast-derived product appeared to be safe and efficacious, and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion."

Advances in Therapy 26(8):795-804, 2009

New to Natural Health?
Tools
Customer Service